Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients.
BACKGROUND
One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic factors for postmastectomy locoregional recurrence (LRR) and survival in those patients.


METHODS
114 patients undergoing mastectomy and adjuvant radiotherapy in Cancer Institute of Tehran University of Medical Sciences were retrospectively reviewed between 1996 and 2008. All cases were followed up after initial treatment of patients with breast cancer via regular visit (annually) for discovering the LRR. Cumulative recurrence free survival (RFS) was determined using the Kaplan-Meier method, with univariate comparisons between groups through the log-rank test. The Cox proportional hazards model was used for multivariate analysis.


RESULTS
The median follow up time was 84 months (range 2-140). Twenty-three (20.2%) patients developed LRR. Cumulative RFS rate at 2.5 years and 5 years were 86% (95%CI, 81-91) and 82.5% (95%CI, 77-87) respectively. Mean RFS was 116.50 +/- 4.43 months (range, 107.82 - 125.12 months, 95%CI). At univariate and multivariate analysis, factors had not any influence on the LRR.


CONCLUSIONS
Despite use of adjuvant therapies during the study, we found a LRR rate after mastectomy of 20.2%. Therefore, for patients with LRR without evidence of distant disease, aggressive multimodality therapy is warranted.
Kheradmand
Ali Arab
AA
Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ranjbarnovin
Neda
N
Khazaeipour
Zahra
Z
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
BMJ. 1991 Jul 20;303(6795):155-8
1878638
Cancer. 1983 Jun 15;51(12 Suppl):2547-52
6342752
Br J Cancer. 1990 Jun;61(6):873-6
2164836
J Clin Oncol. 1999 Jun;17(6):1689-700
10561205
Eur J Cancer. 1990;26(6):668-70
2144152
Eur J Surg Oncol. 1989 Dec;15(6):476-85
2557247
N Z Med J. 1996 Sep 13;109(1029):330-3
8862351
J Natl Cancer Inst Monogr. 1992;(11):7-13
1627432
J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76
17179478
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1337-47
15817335
J Clin Oncol. 2000 Aug;18(15):2817-27
10920129
JAMA. 2007 Jul 18;298(3):289-98
17635889
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1345-52
16750315
Cancer. 2006 Jan 1;106(1):35-41
16333848
Cancer. 2008 Apr 1;112(7):1437-44
18286526
Lancet. 2002 Apr 27;359(9316):1471-7
11988246
World J Surg. 1994 Jan-Feb;18(1):70-5
8197779
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
11577478
Ann Oncol. 2007 May;18(5):859-67
17301074
Arch Surg. 1990 Jun;125(6):771-5; discussion 775-7
2161207
J Natl Cancer Inst Monogr. 1992;(11):27-32
1627428
Med J Aust. 2002 Oct 7;177(7):347-51
12358575
J Natl Cancer Inst. 2005 Jan 19;97(2):116-26
15657341
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):980-8
11958892
J Natl Cancer Inst. 1992 May 6;84(9):683-9
1314910
CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26
8281473
Int J Radiat Oncol Biol Phys. 1986 Jun;12(6):873-8
3721930
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
N Engl J Med. 2007 Jun 7;356(23):2399-405
17554121
Ai Zheng. 2009 Apr;28(4):395-401
19622300
Cancer. 1969 Nov;24(5):1071-80
5353940
Br J Cancer. 1957 Sep;11(3):359-77
13499785
N Engl J Med. 1997 Oct 2;337(14):949-55
9395428
Ann Surg Oncol. 2001 Dec;8(10):828-32
11776498
J Clin Oncol. 2004 Nov 1;22(21):4247-54
15452182
Breast Cancer Res Treat. 2009 Sep;117(1):91-8
19112615
J Natl Cancer Inst. 2001 May 16;93(10):754-62
11353785
Radiother Oncol. 2007 Mar;82(3):247-53
17306393
Arch Surg. 1996 Mar;131(3):301-8
8611096
J Clin Oncol. 1996 Oct;14(10):2738-46
8874335
Eur J Cancer. 1994;30A(3):351-4
8204358